Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
We may earn commission from links on this page, but we only recommend products we love. Promise. Whether you see the invisible string theory as a comforting metaphor, a spiritual belief, or just a fun ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On October 20, 2025, Replimune published a press release announcing that the U.S. Food and Drug Administration (“FDA”) had accepted the resubmission of the Biologics License Application (“BLA”) for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A string trimmer is an invaluable piece of your lawn care tool box. Whether you’re tidying up the edges along sidewalks, freshening in and around flowerbeds, or adding a crisp edge to your driveway, ...
Replimune (REPL) shares plunged ~28% in the premarket on Tuesday after the FDA released a briefing document ahead of an advisory committee meeting scheduled to discuss the marketing application for ...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who ...
Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. RP1 demonstrates real antitumor activity and durable ...
Route Z near Gordonville will close Aug. 24 through Sept. 1 for replacement of the Hubble Creek bridge, MoDOT says. Route Z in Cape Girardeau County, from West Clark Street to County Road 222 near ...
REPL stock surged about 107% at close after an independent panel of experts advised the U.S. Food and Drug Administration in favor of its experimental treatment for advanced melanoma last week. SNOW ...
Iovance Biotherapeutics reported strong Q2 results, with revenue reaching $99.3 million on rising Amtagvi demand. FDA granted Replimune accelerated approval for TUDRIQEV (RP1) combined with nivolumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results